Sarah Mueller Director, European Partnerships.
PhD in Molecular Biology, 12+ years in biotech BD. Specializes in ADC, gene therapy, and rare disease licensing across EU markets.
Biotech vs Pharma: What’s the Difference, and How Do They Work Together?
What a biotech company is and how it differs from pharma: biologics vs small molecules, business models and funding, who discovers new drugs, how the two partner through licensing and M&A, big biotechs, China, careers and investing.
Global Biotech Hubs: The World’s Leading Life Science Clusters and How They Connect
The leading biotech hubs in the US, Europe and Asia, with GEN’s 2026 US cluster data, the Golden Triangle, Basel, Medicon Valley, Shanghai, Suzhou, Hong Kong, Singapore, Tokyo and Songdo, emerging challengers, and how the hubs connect through cross-border deals.
CRO vs CDMO: What Each Does, How They Differ, and How to Choose
A CRO generates the data that gets a drug approved; a CDMO makes the drug. Definitions, the key differences, CRDMOs, the largest providers by 2025 revenue, how contracts are priced, how to choose each, and the BIOSECURE and China angle.
The China CRO Landscape 2026: How Drug Development Gets 30%+ Cheaper
A dealmaker’s guide to the China clinical CRO landscape in 2026 — the named providers (WuXi AppTec, Pharmaron, Tigermed, Novotech and peers), the real cost and speed basis behind the China discount, and how CRO choice plus BIOSECURE exposure shape asset diligence and deal de-risking.
Generative AI in Pharma: What Dealmakers Need to Know
How generative AI differs from predictive AI, where it actually works (molecule and protein design), the FDA’s 2025 stance, the IP and inventorship questions, and what it all means for deals.
Every Humira Biosimilar: The Complete 2026 List
A complete, verified reference list of FDA-approved Humira (adalimumab) biosimilars — manufacturer, approval year, interchangeability status, and concentration — plus the pricing/PBM dynamics and what the Humira playbook means for the next biologics losing exclusivity.
Biosimilar News: Latest FDA Approvals (June 2026)
A regularly-updated biosimilar news digest for dealmakers — recent FDA approvals (denosumab, pertuzumab, ustekinumab, aflibercept, tocilizumab), interchangeability shifts, the Stelara and I/O biosimilar waves, and pricing dynamics — each with a one-line read on why it matters.
The 505(b)(2) Pathway, Explained: A Dealmaker’s Guide
What the FDA 505(b)(2) pathway is, how it differs from a full NDA and an ANDA, eligible product types, bridging studies, patent certifications and exclusivity, and why 505(b)(2) assets are attractive, lower-risk in-licensing candidates.
FDA Breakthrough Therapy Designation: Criteria, Benefits & Strategy
FDA Breakthrough Therapy Designation explained: the criteria, the benefits, how it differs from Fast Track, Accelerated Approval and Priority Review, the grant statistics, the NMPA analog, and what BTD signals in BD diligence and valuation.
FDA Fast Track Designation: What It Is & How to Get It
FDA Fast Track Designation explained: eligibility, benefits, how to request it, and how it relates to Breakthrough Therapy, Accelerated Approval and Priority Review — plus what it signals for cross-border BD and diligence.
Clinical Trial Patient Enrollment: Strategies to Accelerate Recruitment
80% of trials miss enrollment deadlines. Evidence-based strategies for faster patient recruitment — including why China's 2-5x faster enrollment advantage is transforming global drug development timelines.
Biotech Partnerships: Types, Structures & How They Work
A guide to biotech partnership models including co-development, platform licensing, and equity alliances.
CDMO Market Analysis 2026: Size, Trends & Key Players
The CDMO market is worth about $197B (2025) and growing ~7% a year. Key players, BIOSECURE Act impact, regional shifts, and how to choose a CDMO partner.
Gene Therapy Market 2026: Approved Products, Pipeline & Licensing Deals
Zolgensma ($1.24B), Elevidys ($820M+), and CRISPR-based Casgevy are transforming rare disease. Track AAV, CRISPR, and in vivo gene therapy licensing opportunities.
Orphan Drug Designation & Rare Disease Licensing 2026: Market & Strategy Guide
The $217B orphan drug market covers only 5% of rare diseases. 7-year exclusivity, premium pricing, and BioMarin's $4.8B Amicus deal signal massive BD opportunity.
ADC Market 2026: Antibody-Drug Conjugate Pipeline, Deals & Licensing
$14.3B in 2025 sales, Enhertu near $5B, ~400 ADCs in the clinic and 16 FDA approvals. Landmark deals since 2023, China-originated assets, and licensing strategy for BD teams.
CAR-T Cell Therapy Market 2026: Products, Pipeline & Licensing Opportunities
The CAR-T market surpassed $5B with CARVYKTI growing 93% YoY. Allogeneic platforms, autoimmune expansion, and Lilly's $2.4B Orna deal reshape the landscape.
PD-1/VEGF Bispecific Antibody Landscape 2026: Pipeline, Deals & Licensing
Ivonescimab's $5B Summit deal, HARMONi-2 data beating Keytruda, and 9+ pipeline candidates. The hottest bispecific antibody space in oncology.
Obesity and GLP-1 Deals 2026: Who Is Licensing What, and Why
Obesity deal value hit a record in 2026 while GLP-1-targeted deals dried up. Verified 2026 obesity licensing deals, Lilly and Novo sales, and what buyers want next.